Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Clinical trial NCT06413992 · RECRUITING

Trial details

NCT number: NCT06413992
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Endometrial Carcinoma TP53 Mutation Recurrent or Metastatic

Start date: 2024-05-10
Primary completion: 2026-06-01
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.